---
title: Light scattering measurements for better developability assessment of biologic therapeutics
description: App Note - How Merck KGaA uses light scattering measurements for better developability assessment of biologic therapeutics
---

[![DDW-Logo](https://info.edifydigitalmedia.com/hs-fs/hubfs/DDW-Logo.png?width=239&height=121&name=DDW-Logo.png "DDW-Logo")](https://www.edifydigitalmedia.com/)

![Landing Page Banner 1425x400](https://info.edifydigitalmedia.com/hubfs/Landing%20Page%20Banner%201425x400.png "Landing Page Banner 1425x400")

# App Note - **Light scattering measurements for better developability assessment of biologic therapeutics**

 

![Nanotemper_Prometheus_image_180822](https://info.edifydigitalmedia.com/hubfs/Nanotemper_Prometheus_image_180822.jpg "Nanotemper_Prometheus_image_180822")

The ability to monitor biologic candidates' propensity towards self-association is critical for predicting whether a therapeutic is likely to aggregate or become difficult to administer due to viscosity. 

Read how Merck KGaA uses light scattering measurements to predict how formulations will behave at clinically relevant concentrations and find the optimal formulation buffer for their biologics candidates.

You’ll learn about:

- How Merck KGaA uses data from DLS and SLS to rank their candidates for improved downstream success
- Prometheus Panta, an instrument that combines nanoDSF, DLS, and SLS for precise characterization of biologics
- How data from the Prometheus Panta instrument compares with other systems

 

*Brought to you by*

![nanotemper](https://info.edifydigitalmedia.com/hs-fs/hubfs/nanotemper.png?width=142&name=nanotemper.png)

### Download the App Note

## Copyright 2022 Drug Discovery World. All Rights Reserved Privacy Policy & Cookies | Contact | Terms & Conditions